Bio-Rad Signs Second Collaboration Agreement with Caliper

Companies to Investigate Development of Another Novel Microfluidic System 


HERCULES, Calif. and HOPKINTON, Mass., Oct. 25  /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. (Amex: BIO; BIOb) and Caliper Life Sciences, Inc. (NASDAQ:CALP) today announced a new collaboration, under which the companies will study the feasibility of developing a new microfluidics system platform. Details of the new product concept are not being disclosed at this time.

The two companies' previous collaboration, initiated in mid-2003, resulted in the successful launch of a new microfluidics-based electrophoresis product, Experion, in the fall of 2004.

"The success we've enjoyed with the Experion(TM) Automated Electrophoresis System has confirmed our belief that microfluidics is a key strategic technology," commented Norman Schwartz, president and CEO at Bio-Rad. "After our first positive experience collaborating with Caliper, we are looking forward to this next collaboration where we will pursue new ideas regarding LabChip microfluidics as the foundation for innovative new products."

Kevin Hrusovsky, Caliper's president and CEO, also commented, "Bio-Rad is a model partner for our 'Caliper Driven' program, under which we enable life science companies like Bio-Rad to tap into our innovative technologies, expertise and patent portfolio. Their strong reputation in life sciences and diagnostics, and their well-established global distribution very effectively leverage our technology into key markets."

About Bio-Rad:

Bio-Rad Laboratories, Inc. (http://www.bio-rad.com/) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves thousands of research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.

About Caliper Life Sciences:

Caliper Life Sciences uses its leading microfluidics patent estate, innovative automation technologies, and broad assay expertise to accelerate drug discovery, enable diagnosis of disease and facilitate scientific research. With the acquisition of NovaScreen Biosciences in October 2005, Caliper became the first company to provide a comprehensive, central resource for drug discovery products and services.

Caliper headquarters are located in Hopkinton, MA, with R&D, operations and manufacturing facilities for LabChip devices in Mountain View, CA, NovaScreen service operations in Hanover, MD and direct sales, service and applications support throughout the world. The company's customers and "Caliper Driven" partners include many of the largest pharmaceutical, biotechnology, and life sciences companies. http://www.caliperls.com/

NOTE:  LabChip and Caliper are registered trademarks, and Caliper Driven is a trademark, of Caliper Life Sciences, Inc. Experion is a trademark of Bio-Rad Laboratories, Inc.

Various statements made within this press release may constitute "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the companies' expectations. 

DATASOURCE: Caliper Life Sciences, Inc.



CONTACT:  Michele Boudreau, Corporate Communications Director, of Caliper

Life Sciences, [phone], or Jayme Maniatis of Schwartz Communications,

Inc., [phone], or , for Caliper Life Sciences;

or Susan Berg, Corporate Communications Manager, of Bio-Rad Laboratories,

Inc., [phone]



Web site:  http://www.bio-rad.com/

Web site:  http://www.caliperls.com/

Copyright